Non‐canonical RNA ‐binding protein ANXA11 regulates microRNA resorting into small extracellular vesicles to mediate cisplatin resistance
The FASEB Journal · 2024
DOI: 10.1096/fj.202400841r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Yifan Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Cisplatin, Drug Resistance, Neoplasm, Extracellular Vesicles, Laryngeal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), Special Fund for Clinical Research in Health Industry of Shanghai Municipal Health Commission, Shanghai Sailing Program.
Abstract (Originalsprache)
The sensitivity of laryngeal squamous cell carcinoma (LSCC) to chemotherapy shows large heterogeneity. The role of miRNA in small extracellular vesicles (sEV) in chemotherapy resistance is under investigation. However, the regulation and sorting mechanism of sEV miRNAs remains unclear. In this study, small RNA sequencing was used to explore miRNA expression profiles in sEV of LSCC after cisplatin stimulation; RNA pull‐down, mass spectrometry, and EMSA were used to clarify the binding of candidate RNA‐binding protein (RBP) and candidate miRNA. Immunostaining and microRNA fluorescence in situ hybridization were performed to identify how candidate RBP affects miRNA stability and nuclear/cytoplasmic distribution. In vivo experiments were performed to verify the biological functions and response to cisplatin of candidate RBP. We found that cisplatin stimulation induced increased expression of miR‐148a‐3p and sEV sorting. ANXA11 binds to miR‐148a‐3p in a sequence‐specific manner. ANXA11 inhibits tumor cell proliferation and drug resistance by binding to and retaining miR‐148a‐3p. Cisplatin stimulation reduced ANXA11 expression and promoted miR‐148a‐3p efflux through sEV pathways. ANXA11 overexpression reduced in vivo tumor proliferation and cisplatin‐resistance. Taken together, ANXA11 mediates cisplatin resistance through sEV miRNA resorting. Mechanically, ANXA11 binds to miR‐148a‐3p in a sequence‐specific manner to regulate its resorting and thus influences tumor proliferation and chemoresistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Yifan Zhang, Qiang Huang, Yujie Shen, Henglei Ren, Chunping Wu, Liang Zhou
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- Special Fund for Clinical Research in Health Industry of Shanghai Municipal Health Commission
- Shanghai Sailing Program
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Y., Huang, Q., Shen, Y., Ren, H., Wu, C., & Zhou, L. (2024). Non‐canonical RNA ‐binding protein ANXA11 regulates microRNA resorting into small extracellular vesicles to mediate cisplatin resistance. The FASEB Journal. https://doi.org/10.1096/fj.202400841r
Vancouver
Zhang Y, Huang Q, Shen Y, Ren H, Wu C, Zhou L. Non‐canonical RNA ‐binding protein ANXA11 regulates microRNA resorting into small extracellular vesicles to mediate cisplatin resistance. The FASEB Journal. 2024. doi:10.1096/fj.202400841r
BibTeX
@article{Zhang2024,
author = {Zhang, Yifan and Huang, Qiang and Shen, Yujie and Ren, Henglei and Wu, Chunping and Zhou, Liang},
title = {Non‐canonical RNA ‐binding protein ANXA11 regulates microRNA resorting into small extracellular vesicles to mediate cisplatin resistance},
journal = {The FASEB Journal},
year = {2024},
doi = {10.1096/fj.202400841r}
}
EUVIMED